Amgen Inc - Sep 14, 2023 Form 3 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role: 10%+ Owner
Signature: /s/ Peter H. Griffith, Executive Vice President and Chief Financial Officer
Stock symbol: NMRA
Transactions as of: Sep 14, 2023
Transactions value $: $0
Form type: 3
Date filed: 9/14/2023, 06:58 PM
Previous filing: Jan 11, 2022
Next filing: Sep 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NMRA	Series A-2 Preferred Stock							Sep 14, 2023	Common Stock	32.8M		Direct	F1, F2
holding	NMRA	Series B Preferred Stock							Sep 14, 2023	Common Stock	850K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series A-2 Preferred Stock of the Issuer will automatically convert on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
F2	Reflects a 1-for-7.8463 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement on September 8, 2023.
F3	The shares of Series B Preferred Stock of the Issuer will automatically convert on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.